Nicholas valiante
Seminars
Thursday 20th November 2025
A Phase Ia Study to Assess the Safety, Tolerability & Immunogenicity of a Personalized Cancer Vaccine (InnoPCV/INV002) in Patients With Advanced Solid Tumors
1:00 pm
• Overview of Innovac’s approach to optimizing every step of the PCV value chain
• Current regulatory environment for mRNA/LNP personalized cancer vaccine entering Phase 1 clinical trials
• INV002 human safety and tolerability results INV002 neoantigen-specific T cell induction and patient biomarker results
